Libo Pharma Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-296.3	-147.8	-46.41
Depreciation & Amortization	23.55	17.57	4.89
Other Amortization	-	0.1	0.12
Stock-Based Compensation	21.61	23.6	0.5
Other Operating Activities	-1.11	-0.2	-3.17
Change in Accounts Receivable	0.06	0.23	3.61
Change in Accounts Payable	0	-1.03	4.19
Change in Other Net Operating Assets	-96.91	-10.94	0.31
Operating Cash Flow	-349.1	-118.47	-35.96
Capital Expenditures	-0.56	-1.36	-0.05
Sale (Purchase) of Intangibles	-0.44	-172.24	-0.17
Investment in Securities	-	-	44.45
Other Investing Activities	0.03	-0.08	-
Investing Cash Flow	-0.97	-173.68	44.23
Long-Term Debt Repaid	-1.66	-1.15	-1.05
Net Debt Issued (Repaid)	-1.66	-1.15	-1.05
Issuance of Common Stock	877.33	493.47	1.08
Financing Cash Flow	875.67	492.32	0.03
Net Cash Flow	525.6	200.16	8.3
Free Cash Flow	-349.66	-119.84	-36.01
Free Cash Flow Per Share	-5.59	-3.20	-1.36
Cash Interest Paid	-	0.05	0.07
Cash Income Tax Paid	-	0.2	0.23
Levered Free Cash Flow	-267.62	-239.68	-
Unlevered Free Cash Flow	-267.59	-239.65	-
Change in Working Capital	-96.84	-11.73	8.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.